The Precision Oncology Program for Cancer of the Prostate (POPCaP) Network: A Veterans Affairs/Prostate Cancer Foundation Collaboration.
Journal
Federal practitioner : for the health care professionals of the VA, DoD, and PHS
ISSN: 1078-4497
Titre abrégé: Fed Pract
Pays: United States
ID NLM: 9500574
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
entrez:
10
9
2020
pubmed:
11
9
2020
medline:
11
9
2020
Statut:
ppublish
Résumé
The promise of precision oncology only can be realized when genetic alterations are identified that can be lever-aged to improve response and minimize toxicity. Identifying those alterations as efficiently as possible and then giving patients access to targeted therapy and clinical study requires a comprehensive strategy across health care systems. The US Department of Veterans Affairs (VA) and Prostate Cancer Foundation have established a network of VA centers to help develop best practices for precision oncology for the treatment of veterans with advanced prostate cancer. This article describes the genesis and structure of this network and its potential for contributing to care and research in the VA and the health care system as a whole. The Precision Oncology Program for Cancer of the Prostate network and its partnership with VA clinical and research efforts is anticipated to provide important insights into barriers and solutions to the implementation of precision oncology for prostate cancer across the VA.
Sections du résumé
BACKGROUND
BACKGROUND
The promise of precision oncology only can be realized when genetic alterations are identified that can be lever-aged to improve response and minimize toxicity. Identifying those alterations as efficiently as possible and then giving patients access to targeted therapy and clinical study requires a comprehensive strategy across health care systems.
OBSERVATIONS
METHODS
The US Department of Veterans Affairs (VA) and Prostate Cancer Foundation have established a network of VA centers to help develop best practices for precision oncology for the treatment of veterans with advanced prostate cancer. This article describes the genesis and structure of this network and its potential for contributing to care and research in the VA and the health care system as a whole.
CONCLUSIONS
CONCLUSIONS
The Precision Oncology Program for Cancer of the Prostate network and its partnership with VA clinical and research efforts is anticipated to provide important insights into barriers and solutions to the implementation of precision oncology for prostate cancer across the VA.
Identifiants
pubmed: 32908353
doi: 10.12788/fp.0021
pii: fp-37-7s-s48
pmc: PMC7473728
doi:
Types de publication
Journal Article
Langues
eng
Pagination
S48-S53Informations de copyright
Copyright © 2020 Frontline Medical Communications Inc., Parsippany, NJ, USA.
Déclaration de conflit d'intérêts
Author Disclosures The authors reports no actual or potential conflicts of interest with regard to this article.
Références
Am Soc Clin Oncol Educ Book. 2018 May 23;38:726-739
pubmed: 30231382
Cell. 2018 Jul 26;174(3):758-769.e9
pubmed: 30033370
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
N Engl J Med. 1998 Sep 24;339(13):924-5
pubmed: 9750095
Cancer Epidemiol Biomarkers Prev. 2014 Mar;23(3):437-49
pubmed: 24425144
JAMA Oncol. 2019 Apr 1;5(4):471-478
pubmed: 30589920
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
PLoS One. 2020 May 26;15(5):e0233260
pubmed: 32453797
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
N Engl J Med. 2016 Nov 3;375(18):1804-5
pubmed: 27806229